United TherapeuticsFRA:UTH -2.65%84 ROA % is 15.17% as of Mar. 2026, which is 2% below its 10-year median of 15.49. GuruFocus rates FRA:UTH with a GF Score™ of 84/100 and a GF Value™ of €337.25 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,003 Drug Manufacturers companies, United Therapeutics ranks better than 94.12% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. United Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was €951 Mil.
United Therapeutics's average Total Assets over the quarter that ended in Mar. 2026 was €6,269 Mil. Therefore, United Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was 15.17%.
The historical rank and industry rank for United Therapeutics's ROA % or its related term are showing as below:
FRA:UTH'
s ROA % Range Over the Past 10 Years
Min: -2.86 Med: 15.49 Max: 31.65
Current: 17.12
During the past 13 years, United Therapeutics's highest ROA % was 31.65%. The lowest was -2.86%. And the median was 15.49%.
FRA:UTH's ROA % is ranked better than 94.12% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.69
vs FRA:UTH: 17.12
United Therapeutics (FRA:UTH) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
United Therapeutics ROA % Related Terms
United Therapeutics ROA % Historical Data
* Premium members only.
The historical data trend for United Therapeutics's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's ROA % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
United Therapeutics (FRA:UTH) has a ROA % of 15.17% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on United Therapeutics and its competitors. This is near median its historical median of 15.49. According to the industry distribution chart, United Therapeutics ranks #59 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 5.9%.
Is United Therapeutics' ROA % too high?
United Therapeutics' current ROA % of 15.17% is near median its 10-year median of 15.49. The Drug Manufacturers industry median ROA % is 2.69. United Therapeutics' value of 15.17% is 463.9% above this industry median. Based on the distribution chart, United Therapeutics ranks #59 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' ROA % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #59 out of 1003 companies for ROA %. This places United Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. United Therapeutics' value of 15.17% is 463.9% above this benchmark. While the company's 10-year median is 15.49 vs. the industry median of 2.69, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current ROA % of 15.17% is 463.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current ROA % is 15.17%, which is near median its own 10-year median of 15.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €337.25, compared to a current price of €473.30 — trading 40.3% above its estimated fair value. The current ROA % is 15.17%, which is near median its 10-year median of 15.49 and 463.9% above the Drug Manufacturers industry median of 2.69. United Therapeutics' overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current ROA % is 15.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (FRA:UTH) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of €473.30 is trading 40.3% above its estimated GF Value™ of €337.25.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:UTH:
ROA %: 15.17% (near median its 10-year median of 15.49)
GF Value™: €337.25 vs. price of €473.30 (40.3% above fair value)
Industry Position: 463.9% above the Drug Manufacturers median (#59 of 1003)
No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
84GF Score
Get the complete analysis for FRA:UTH
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTH has been successfully added to your 
